Ann: Imugene and Eureka Therapeutics onCARlytics Collaboration, page-13

Good find @stevouk

You got me thinking and researching.

Article from Nov 2018 where Yuman makes a comment about Eureka:

https://www.scientificamerican.com/custom-media/eureka-frontiers-in-t-cell-therapy/the-tell-tale-targets-hidden-inside-solid-tumors/

"A recent proof-of-concept study, presented at the 2018 CAR-TCR Summit, highlighted Eureka’s T cell therapy. The first-in-human study enrolled six patients with advanced liver cancer—for whom current therapies offer little hope. Eureka’s T cells are activated by a unique but highly expressed liver cancer biomarker: alpha fetoprotein (AFP). “In this early experience, [the treatment] is well tolerated with no signs of CRS or neurotoxicity,” says Yuman Fong, a hepatobiliary cancer surgeon at California-based City of Hope, who reviewed data from the clinical study. Six months after the first dose in the study, the best-responding patient experienced a complete reduction in his primary tumors and distal metastases, while his AFP levels dropped to normal (see ‘Healing Hope’). Fong says, “If these data hold up, such a new design of T cell therapy may truly transform this field to an out-patient clinical field — making it not only lower cost, but potentially accessible to the entire world.” He adds, “Even though this is still early data, to see generalized shrinkage of tumor and normalization of blood tumor markers is remarkable.”


Yuman Fong is also on the Advisory board of the Miami Cancer Research Center. Maybe something might evolve with them.
https://miamicancerresearch.org/about/advisory/